Separation Science: Driving Pharmaceutical Development and Manufacture
The Chromatographic Society and the Royal Society of Chemistry Analytical Division North East Region has organized a meeting to be held on 22 November 2018 in the Stadium of Light, Sunderland, UK.
Photo Credit: The Chromatographic Society
The Chromatographic Society and the Royal Society of Chemistry Analytical Division North East Region has organized a meeting to be held on 22 November 2018 in the Stadium of Light, Sunderland, UK.
The organizers are planning to make the conference a little different than usual. The meeting will not be introducing new chromatographic innovations to pharmaceutical researchers. Instead, the conference will reflect on the enduring strength of pharmaceutical development and manufacture in the UK. The unmet analytical challenges facing these areas of the industry will be explored and emerging technologies reviewed to assess those that potentially offer the best solutions for the immediate future. Ahead of the meeting analytical scientists supporting pharmaceutical development and manufacture will be invited to comment on the most important unmet analytical needs they are facing, with a view to speakers and vendors responding at the meeting. For more information, please visit: http://chromsoc.com/event/seperation-science-driving-pharmaceutical-development-and-manufacture
For initial enquiries please contact:
Scientific programme: john.lough@sunderland.ac.uk
Exhibition opportunities: heather.linnell@agilent.com
Local arrangements: roger.reeve@sunderland.ac.uk
New TRC Facility Accelerates Innovation and Delivery
April 25th 2025We’ve expanded our capabilities with a state-of-the-art, 200,000 sq ft TRC facility in Toronto, completed in 2024 and staffed by over 100 PhD- and MSc-level scientists. This investment enables the development of more innovative compounds, a broader catalogue and custom offering, and streamlined operations for faster delivery. • Our extensive range of over 100,000 high-quality research chemicals—including APIs, metabolites, and impurities in both native and stable isotope-labelled forms—provides essential tools for uncovering molecular disease mechanisms and exploring new opportunities for therapeutic intervention.
New Guide: Characterising Impurity Standards – What Defines “Good Enough?”
April 25th 2025Impurity reference standards (IRSs) are essential for accurately identifying and quantifying impurities in pharmaceutical development and manufacturing. Yet, with limited regulatory guidance on how much characterisation is truly required for different applications, selecting the right standard can be challenging. To help, LGC has developed a new interactive multimedia guide, packed with expert insights to support your decision-making and give you greater confidence when choosing the right IRS for your specific needs.
